Literature DB >> 8107208

An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.

E S Robertson1, B Tomkinson, E Kieff.   

Abstract

A family of Epstein-Barr virus (EBV)-encoded RNAs found in nasopharyngeal carcinoma cells is also present at low levels in some latently infected and growth-transformed B lymphocytes (P. R. Smith, Y. Gao, L. Karran, M. D. Jones, D. Snudden, and B. E. Griffin, J. Virol. 67:3217-3225, 1993). A molecular genetic approach using EBV recombinants was undertaken to evaluate the role of these transcripts in primary B-lymphocyte growth transformation and latent infection. Since the se transcripts arise from a 22-kbp segment of the EBV genome and construction of large deletion mutants is an improbable result after transfection of infected cells with an EBV DNA fragment with a large deletion mutation, a new approach was taken to make a recombinant with the DNA encoding all of the BARF0 RNAs deleted. The approach derives from a recently described strategy for making recombinants from five overlapping EBV cosmid-cloned DNAs (B. Tomkinson, E. Robertson, R. Yalamanchili, R. Longnecker, and E. Kieff, J. Virol. 67:7298-7306, 1993). A large segment of EBV DNA was deleted from the transfected cosmid DNAs by omitting a cosmid which included all of the DNA encoding the BARF0 RNA and by ligating the distal halves of the two flanking cosmids so as to create one cosmid which had ends that overlapped with the other two unaltered cosmids. EBV recombinants with 58 kbp including BARF0 deleted resulted from transfecting the three overlapping EBV DNA fragments into P3HR-1 cells and simultaneously inducing lytic replication of the endogenous, transformation-defective, P3HR-1 EBV. The endogenous P3HR-1 EBV provided lytic infection and packaging functions. EBV recombinants with intact transforming functions were then selected by infecting primary B lymphocytes and growing the resultant transformed cells in lymphoblastoid cell lines. The efficiency of incorporation of the deletion into transforming EBV recombinants was close to that of a known indifferent marker, the type 1 EBNA 3A gene, indicating the absence of significant selection against the deletion. Cells infected with the deleted recombinant grew similarly to those infected with wild-type recombinants and had a similar level of permissiveness for lytic EBV infection. Thus, the BARF0 transcript is not critical to primary B-lymphocyte growth transformation or to latent infection. This methodology is useful for constructing EBV recombinants which are specifically mutated at other sites in the three cosmids and is a step toward deriving a minimal transforming EBV genome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107208      PMCID: PMC236600     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups.

Authors:  W Henle; G Henle; H C Ho; P Burtin; Y Cachin; P Clifford; A de Schryver; G de-Thé; V Diehl; G Klein
Journal:  J Natl Cancer Inst       Date:  1970-01       Impact factor: 13.506

2.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

4.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

Authors:  K Nilsson; G Klein; W Henle; G Henle
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

5.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

6.  Cultivation and fine structure of virus-bearing lymphoblasts from a second New Guinea Burkitt lymphoma: establishment of sublines with unusual cultural properties.

Authors:  J H Pope; B G Achong; M A Epstein
Journal:  Int J Cancer       Date:  1968-03-15       Impact factor: 7.396

7.  Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells.

Authors:  M Heller; T Dambaugh; E Kieff
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103

8.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

9.  Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.

Authors:  T Shope; D Dechairo; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

10.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

View more
  41 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

3.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

Review 4.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.

Authors:  N Shimizu; H Yoshiyama; K Takada
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.

Authors:  K M Izumi; K M Kaye; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus.

Authors:  K L Fries; T B Sculley; J Webster-Cyriaque; P Rajadurai; R H Sadler; N Raab-Traub
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses.

Authors:  Pierre Rivailler; Young-Gyu Cho; Fred Wang
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

9.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.

Authors:  I K Ruf; A Moghaddam; F Wang; J Sample
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.